Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    200%(2 trials)
    Terminated
    1(50%)

    Phase Distribution

    Phase 3
    1
    50%
    Phase 1/2
    1
    50%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 1/2Combined phases
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(1)
    Terminated(1)

    Detailed Status

    Terminated1
    Completed1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 1/21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    terminated150%
    completed150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completedphase_1_2

    A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

    NCT00587587
    terminatedphase_3

    Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

    NCT00587223

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT00587587Phase 1/2

    A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

    Completed
    NCT00587223Phase 3

    Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

    Terminated

    All 2 trials loaded

    Drug Details

    Intervention Type
    Other
    Total Trials
    2